t Research Fellow (HF-8395-CI), National Heart Institute, Bethesda, Md. metabolic product of that drug was an agent capable of damaging red cells which might even produce in vitro hemolysis.
Previous studies (2) have demonstrated that prelytic increased cation permeability induced in normal erythrocytes by primaquine is a more sensitive indicator of in vitro damage to the cells than is hemolysis. This increased permeability, manifested by loss of K+ from normal erythrocytes is produced by concentrations of primaquine or acetylphenylhydrazine which are 3 x 10-4 M or greater. These in vitro concentrations of primiaquine appear to have serious deleterious effect on the red cell membrane. Desforges, Kalaw and Gilchrist (4) have demonstrated noncompetitive inhibition of glucose-6-phosphate dehydrogenase by 1 X 10-3 M primaquine. Mohler All the blood samples were subjected to the screening test of Motulsky, Kraut, Thieme and Musto (7) for decreased glucose-6-phosphate dehydrogenase activity and found to be abnormal. Glutathione stability tests were conducted as outlined by Beutler (8) and demonstrated abnormally low, postincubation reduced glutathione content of the erythrocytes of all the donors except for the female patient. This patient's reduced glutathione values were 48.5 mg per 100 ml initially and 27.5 mg per 100 ml after incubation with acetylphenylhydrazine.
The conditions of in vitro incubation of erythrocytes with primaquine and techniques for measuring loss of K+, osmotic fragility, reduced glutathione, primaquine and hemolysis are described in an accompanying paper (2) . The in vitro concentrations of primaquine 1 employed ranged from 1 X 10' to 3 X 10' M. Loss of K+ after in vitro exposure of red cells to the drug was studied on samples of blood from 3 primlaquine-sensitive individuals and 1 individual whose glutathione stability test 1)laced her in the intermediate group.
In an effort to evaluate the role of metabolic products of primaquine, experiments were conducted in which red cells from 2 primaquine-sensitive individuals were incubated with serologically compatible serum from 2 normal individuals who had ingested primaquine diphosphate, 30 mg per day, for 3 to 5 days, the last dose being taken 4 hours prior to donation of the serum. The concentration of primaquine present in these sera ranged from 1 to 3 X 10' M. The primaquine-containing sera were incubated with autogenous red cells, and with serologically compatible cells from 2 of the glucose-6-phosphate de prior to ingestion of primaquine were also incubated with the abnormal cells. Incubations without added glucose in the system were extended to 20 hours in the hope of accentuating any differences between normal and abnormal erythrocytes.
RESULTS
Incubation of "sensitive" erythrocytes with priniiaquine. The abnormal red cells were incubated with primaquine in a range of concentrations described above, and in Figure 1 the results of 2-hour incubation studies are compared with similar results obtained from study of normal cells. It is evident, under these circumstances, that the abnormal cells behave no differently from the normal cells and apparently require the same in vitro dosage of primaquine to induce prelytic loss of K+.
Short-term incubation (up to 5 hours) of normal or primaquine-sensitive red cells, either in their own serum or in the serum from normal donors who had taken the drug, produced no significant loss of K+ or hemnolysis. Incubation of these combinations of red cells and serum for 20 hours, in the absence of glucose. yielded the results shown in Table I .
In addition, incubation of a whole blood sample taken from the individual with active hemolvtic 
